NEOGENOMICS INC — Director's Dealing 2023

Dec 5, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2023-12-01

Reporting Person: Stone Warren (President, Clinical Services)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-01	Common Stock	F	5431	—	Disposed	83775	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$11.21	2029-12-01	Common Stock (166113)	166113	Direct
Stock Option (Right to Buy)	$19.65	2030-05-11	Common Stock (53969)	53969	Direct
Restricted Stock Unit	$0		Common Stock (28838)	28838	Direct
Performance Stock Unit	$0		Common Stock (21204)	21204	Direct

Footnotes

F1: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the December 1, 2023 vesting of restricted stock.

F2: On December 1, 2022, Mr. Stone was granted 166,113 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F3: On May 11, 2023, Mr. Stone was granted 53,969 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F4: On May 11, 2023, Mr. Stone was granted 28,838 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.

F5: Once vested, the shares of common stock are not subject to expiration.

F6: On May 11, 2023, Mr. Stone was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 31,806. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.